中山大学孙逸仙纪念医院心血管内科,广东 广州 510120
蒙媛丽,医学硕士,住院医师,研究方向:心血管疾病的超声诊断,E-mail:Mengdatou1990@163.com
纸质出版日期:2023-01-20,
收稿日期:2022-11-03,
扫 描 看 全 文
蒙媛丽,冯日清,王培伟等.Takotsubo综合征患者住院死亡危险因素[J].中山大学学报(医学科学版),2023,44(01):122-130.
MENG Yuan-li,FENG Ri-qing,WANG Pei-wei,et al.Risk Factors for in-Hospital Mortality in Patients with Takotsubo Syndrome[J].Journal of Sun Yat-sen University(Medical Sciences),2023,44(01):122-130.
蒙媛丽,冯日清,王培伟等.Takotsubo综合征患者住院死亡危险因素[J].中山大学学报(医学科学版),2023,44(01):122-130. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2023.0117.
MENG Yuan-li,FENG Ri-qing,WANG Pei-wei,et al.Risk Factors for in-Hospital Mortality in Patients with Takotsubo Syndrome[J].Journal of Sun Yat-sen University(Medical Sciences),2023,44(01):122-130. DOI: 10.13471/j.cnki.j.sun.yat-sen.univ(med.sci).2023.0117.
目的
2
探讨Takotsubo综合征(TTS)患者住院死亡的危险因素。
方法
2
回顾性分析我院2009年2月至2022年1月诊断为TTS患者的住院资料,根据住院期间是否死亡分为死亡组和存活组,比较两组患者的一般临床资料、诱发因素、实验室检查、心电图、超声心动图、并发症和治疗措施,采用单因素logistic回归分析筛选TTS患者住院死亡可能的危险因素,多因素 logistic 回归分析确定TTS患者住院死亡的危险因素。
结果
2
本研究共纳入TTS患者62例,其中男21例(33.9%),女41例(66.1%),绝经后女性26例(41.9%),年龄(55.6±16.2)岁,躯体应激50例(80.6%)。住院期间死亡17例(27.4%),存活45例(72.6%)。TTS死亡组收缩压、左室射血分数(LVEF)较存活组低,其发生晕厥比例、氨基末端B型利钠肽前体(NT-proBNP)及高敏肌钙蛋白T(hs TnT)水平均较存活组高(
P
值均<0.05);诱发因素中,死亡组由于神经系统疾病所诱发TTS的比例高于存活组(
P
<0.05);死亡组发生心原性休克、恶性室性心律失常、心房颤动、呼吸衰竭及治疗用多巴胺、治疗用去甲肾上腺素、血液透析及机械通气的比例均较存活组高(
P
值均<0.05)。单因素logistic回归分析显示,晕厥、NT-proBNP、LVEF、神经系统疾病、心原性休克、恶性室性心律失常、心房颤动、呼吸衰竭、治疗用多巴胺、治疗用去甲肾上腺素、血液透析及机械通气是TTS患者住院死亡的可能危险因素(
P
值均<0.05)。多因素logistic回归分析显示,神经系统疾病[OR(95%CI)=5.651(1.195,26.715),
P
=0.029]、心房颤动[OR(95%CI)=6.217(1.276,30.298),
P
=0.024]、治疗用去甲肾上腺素[OR(95%CI)=8.847(1.912,40.949),
P
=0.005]是TTS患者住院死亡的独立危险因素。
结论
2
神经系统疾病、心房颤动、治疗用去甲肾上腺素是TTS患者住院死亡的独立危险因素,临床上需注意神经系统疾病、心房颤动的防治,对于已确诊TTS合并血流动力学不稳定患者需慎重使用去甲肾上腺素。
Objective
2
To analyze the risk factors for in-hospital mortality in patients with Takotsubo Syndrome (TTS).
Methods
2
Hospitalization data of consecutive patients with TTS from February 2009 to January 2022 were retrospectively collected and analyzed. Patients were divided into survival group and death group according to outcomes. The basic clinical information, triggering factors, laboratory examinations, electrocardiogram, echocardiography, complications and treatments of the two groups were compared. Univariable logistic regression analysis was used to screen the possible risk factors for in-hospital mortality in TTS patients, and multivariable logistic regression analysis was used to determine the independent risk factors for in-hospital mortality in TTS patients.
Results
2
A total of 62 TTS patients were included in our study, including 21 males (33.9%), 41 females (66.1%) and 26 postmenopausal women (41.9%), with the mean age of (55.6±16.2) years, and physical triggers were found in 50 patients (80.6%). 17 patients (27.4%) died while 45 patients (72.6%) survived during hospitalization. The death group had lower systolic blood pressure and left ventricular ejection fraction (LVEF), higher incidence rate of syncope, higher level of N-terminal pro-B natriuretic peptide (NT-proBNP) and hypersensitive troponin T (hs TnT) when compared with survival group (all
P
value
<
0.05). As for the triggering factors, the proportion of TTS induced by neurologic disorders in the death group was higher than that in the survival group (
P
<
0.05). The death group had higher rates of cardiogenic shock, malignant ventricular arrhythmia, atrial fibrillation, and respiratory failure (all
P
value
<
0.05). Compared with the survival group, therapeutic dopamine, therapeutic norepinephrine, hemodialysis and mechanical ventilation were higher in the death group (all
P
value
<
0.05). Univariable logistic regression analysis suggested that syncope, NT-proBNP, LVEF, neurologic disorders, cardiogenic shock, malignant ventricular arrhythmia, atrial fibrillation, respiratory failure, therapeutic dopamine, therapeutic norepinephrine, hemodialysis and mechanical ventilation were potential risk factors for in-hospital mortality in TTS patients (all
P
value
<
0.05). Multivariable logistic regression analysis indicated that neurologic disorders [OR(95%CI)=5.651(1.195,26.715),
P
=0.029], atrial fibrillation [OR(95%CI)=6.217(1.276,30.298),
P
=0.024)] and therapeutic norepinephrin [OR(95%CI)=8.847(1.912,40.949),
P
=0.005] were independent risk factors for in-hospital mortality in TTS patients.
Conclusions
2
Neurologic disorders, atrial fibrillation and therapeutic norepinephrin are independent risk factors for in-hospital mortality in patients with Takotsubo Syndrome. Clinically, attention should be paid to the prevention and treatment of neurologic disorders and atrial fibrillation; norepinephrine should be carefully used in patients with diagnosed TTS complicated with hemodynamic instability.
Takotsubo综合征住院死亡危险因素
Takotsubo syndromein-hospital mortalityrisk factors
Ghadri JR, Wittstein IS, Prasad A, et al. International expert consensus document on Takotsubo syndrome (Part I): clinical characteristics, diagnostic criteria, and pathophysiology[J]. Eur Heart J, 2018, 39(22): 2032–2046.
Gili S, Cammann VL, Schlossbauer SA, et al. Cardiac arrest in Takotsubo syndrome: results from the InterTAK Registry[J]. Eur Heart J, 2019, 40(26): 2142–2151.
Di Vece D, Citro R, Cammann VL, et al. Outcomes associated with cardiogenic shock in Takotsubo syndrome[J]. Circulation, 2019, 139(3): 413–415.
Ghadri JR, Wittstein IS, Prasad A, et al. International expert consensus document on Takotsubo syndrome (Part Ⅱ): diagnostic workup, outcome, and management[J]. Eur Heart J, 2018, 39(22): 2047–2062.
Medina de Chazal H, Del Buono MG, Keyser-Marcus L, et al. Stress cardiomyopathy diagnosis and treatment: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2018, 72(16):1955–1971.
Nagata T, Mohri M. The clinical features and outcomes of patients with Takotsubo syndrome: the experience at an emergency general hospital[J]. Intern Med, 2018, 57(5):641-645.
陈洪波, 张艳, 宿英英. 急性重症脑卒中患者脑心交互现象的临床特点与预后分析[J]. 中华危重病急救医学, 2019, 31(8): 953-957.
Chen HB, Zhang Y, Su YY. Clinical characteristics and prognosis of brain-heart interaction in patients with acute severe stroke[J]. Chin Crit Care Med, 2019, 31(8): 953-957.
Ghadri JR, Cammann VL, Napp LC, et al. International Takotsubo (InterTAK) Registry. Differences in the clinical profile and outcomes of typical and atypical Takotsubo syndrome: data from the International Takotsubo Registry[J]. JAMA Cardiol, 2016, 1(3): 335-340.
Ghadri JR, Kato K, Cammann VL, et al. Long term prognosis of patients with Takotsubo syndrome[J]. J Am Coll Cardiol, 2018, 72(8): 874–882.
Cammann VL, Scheitz JF, von Rennenberg R, et al. InterTAK consortium. Clinical correlates and prognostic impact of neurologic disorders in Takotsubo syndrome[J]. Sci Rep, 2021, 11(1): 23555.
Sposato LA, Hilz MJ, Aspberg S, et al. World Stroke Organisation Brain & Heart Task Force. Post-stroke cardiovascular complications and neurogenic cardiac injury: JACC state-of-the-art review[J]. J Am Coll Cardiol, 2020, 76(23): 2768-2785.
Chen Z, Venkat P, Seyfried D, et al. Brain-Heart Interaction: cardiac complications after stroke[J]. Circ Res, 2017, 121(4): 451-468.
El-Battrawy I, Lang S, Ansari U, et al. Impact of concomitant atrial fibrillation on the prognosis of Takotsubo cardiomyopathy[J]. Europace, 2017, 19(8):1288-1292.
Jesel L, Berthon C, Messas N, et al. Atrial arrhythmias in Takotsubo cardiomyopathy: incidence, predictive factors, and prognosis[J]. Europace, 2019, 21(2): 298-305.
El-Battrawy I, Cammann VL, Kato K, et al. Impact of atrial fibrillation on outcome in Takotsubo syndrome: data from the International Takotsubo Registry[J]. J Am Heart Assoc, 2021, 10(15): e014059.
Stiermaier T, Santoro F, Eitel C, et al. Prevalence and prognostic relevance of atrial fibrillation in patients with Takotsubo syndrome[J]. Int J Cardiol, 2017, 245:156-161.
刘君, 赖俊, 何咏聪, 等. 酷似急性心肌梗死的Takotsubo 综合征临床特点及预后分析[J]. 中山大学学报(医学科学版),2020, 41(4): 627-634.
Liu J, Lai J, He YC, et al. Clinical charateristics and prognosis of Takotsubo syndrome mimicking acute myocardial infarction[J]. J SUN Yat⁃sen Univ(Med Sci),2020, 41(4): 627-634.
Kido K, Guglin M. Drug-induced Takotsubo cardiomyopathy[J]. J Cardiovasc Pharmacol Ther, 2017, 22(6): 552-563.
Paur H, Wright PT, Sikkel MB, et al. High levels of circulating epinephrine trigger apical cardiodepression in a β2-adrenergic receptor/Gi-dependent manner: a new model of Takotsubo cardiomyopathy[J]. Circulation, 2012, 126(6): 697–706.
Vieira A, Batista B, de Abreu TT. Iatrogenic Takotsubo cardiomyopathy secondary to norepinephrine by continuous infusion for shock[J]. Eur J Case Rep Intern Med, 2018, 5(7):000894.
Y-Hassan S, Henareh L. Plasma catecholamine levels in patients with Takotsubo syndrome: implications for the pathogenesis of the disease[J]. Int J Cardiol. 2015;181:35-38.
Y-Hassan S, Falhammar H. Clinical features, complications, and outcomes of exogenous and endogenous catecholamine-triggered Takotsubo syndrome: a systematic review and meta-analysis of 156 published cases[J]. Clin Cardiol, 2020, 43(5): 459-467.
Sato K, Iwata A, Kurihara M, et al. Stress cardiomyopathy (Takotsubo syndrome) in patients who received adrenergic agonist drugs: a pharmacovigilance study using the Japanese Adverse Drug Event Report (JADER) database[J]. J Cardiol, 2022, 79(1): 36-41.
Ansari U, El-Battrawy I, Fastner C, et al. Clinical outcomes associated with catecholamine use in patients diagnosed with Takotsubo cardiomyopathy[J]. BMC Cardiovasc Disord, 2018, 18(1): 54.
Singh T, Khan H, Gamble DT, et al. Takotsubo syndrome: pathophysiology, emerging concepts, and clinical implications[J]. Circulation, 2022, 145(13): 1002-1019.
Redmond M, Knapp C, Salim M, et al. Use of vasopressors in Takotsubo cardiomyopathy: a cautionary tale[J]. Br J Anaesth, 2013, 110(3): 487–488.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构